Research impact.

 

Prize-Winning Mentorship (Prof. Des Richardson)

Awards and Achievements

  1. 15 of 18 University of Sydney students (83%) have received the prestigious Peter Bancroft Prize for an Outstanding PhD Thesis without Corrections.

  2. University of Sydney Vice-Chancellor’s Award for Excellence in Research Higher Degree Supervision and awarded a Citation by the Office of Learning & Teaching from the Australian Government.

  3. The Mutagenesis and Experimental Pathology Society of Australasia (MEPSA) “Old Farts” Award by Trainees as the Most Supportive Academic Award.

  4. International Society for Redox Biology & Medicine (SfRBM) Mentoring Excellence Award for Trainee Mentorship Award.

  5. Many outstanding PhD-students/postdocs have been “stars” receiving multiple prizes/medals (published 6-24 publications during their PhD) and gone on to 23-prestigious National/International Fellowships ($400,000- 2 600,000 each) e.g., NHMRC-Peter Doherty/NHMRC CJ-Martin/NHMRC-RD Wright/Cancer Institute NSWFellowships/NHF-John Shaw Fellowship (for top-ranked NHF-Fellow)/MDA USA Early Career Grant/Friedreich’s Ataxia Research-Alliance USA Fellowship).

Invited Talks, Plenary and Distinguished Speaker Presentations (2021)

(1) Richardson, D.R. (2021) Overcoming the Triad of Death in Cancer by Developing Frontier, Anti-Cancer Drugs for the Treatment of Deadly Childhood Neuroblastoma. Tour de Cure – Soiree for a Cure. Hilton Hotel, Brisbane. February 6th +++ Lay audience. This fund raising night for my research program raised $300,000, of which $150,000 funded my Tour de Cure Senior Research Grant.

(2) Richardson, D.R. (2021) Development of Novel Anti-Cancer Drugs that Target the” Triad of Death” in Cancer. Moreton Bay Regional Prostate Cancer Support Group, Brisbane, Queensland. February 9th. +++ Lay audience.*

(3) Richardson, D.R. (2021) Targeting cellular signalling to inhibit tumour cell metastasis and growth: The iron and NDRG1 connection. Invited and Sponsored Symposium: “Role of Redox-Active Metals for the Prevention and Treatment of Cancer in the Era of Precision Medicine” 20th Biennial Meeting for the Society of Free Radical Research International (SFRRI 2021), Chang Gung University of Science and Technology, Taiwan. 16th  March 2021.*

(4) Richardson, D.R. (2021) Innovative anti-cancer agents that inhibit metastasis, resistance and primary tumour growth. Department of Chemistry, Central University of Karnataka, Kadaganchi, Aland Road, Kalaburagi-585 311, Karnataka, India. May  14th. Distinguished Lecture Series.*

(5) Richardson, D.R. (2021) Targeting metastasis in cancer through the metastasis suppressor, NDRG1, using innovative therapeutics. 7th International Meeting of Nanomaterials and Nanotechnologies (NanoOstrava-21), Ostrava, Czech Republic, in May 17-20, 2021. Plenary Speaker*

(6) Richardson, D.R. (2021) An innovative therapeutic approach to inhibit bi-directional oncogenic cross-talk between pancreatic cancer cells and the surrounding stroma. Queensland Institute for Medical Research Berghofer, Brisbane, Queensland. June 15th

(7) Richardson, D.R. Tricking transporters to overcome resistance in cancer: Targeting P-glycoprotein (2021) University of Queensland, St. Lucia, Brisbane, Queensland. 28th June.

(8) Richardson, D.R. (2021) Targeting the lysosome: The development of anti-cancer agents with marked and selective anti-tumour activity. Adcentrx Therapeutics LLC, San Diego, USA. 30/7/2021